VERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program VXA-222 from Joint Discovery Collaboration with OmniAb

VERAXA Biotech recently announced that their bispecific antibody-drug conjugate (ADC) program, VXA-222, developed in collaboration with OmniAb, has progressed to the next phase at VERAXA. This significant advancement comes after the successful attainment of a crucial technical milestone. VXA-222 holds promise in the field of biotechnology and is set to revolutionize treatment strategies with its innovative approach. This development marks a milestone in the collaboration between VERAXA and OmniAb, highlighting their commitment to advancing cutting-edge research in the biopharmaceutical industry.